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Objectives We sought to analyze the composition of coronary thrombus in vivo in ST-segment elevation myocardial infarc-
tion (STEMI) patients.
Background The dynamic process of intracoronary thrombus formation in STEMI patients is poorly understood.
Methods Intracoronary thrombi (n  45) were obtained by thromboaspiration in 288 consecutive STEMI patients present-
ing for primary percutaneous intervention, and analyzed using high-definition pictures taken with a scanning
electron microscope. Plasma biomarkers (TnI, CRPus, IL-6, PAI-1, sCD40 ligand, and TNF-) and plasma fibrin
clot viscoelastic properties were measured simultaneously on peripheral blood.
Results Thrombi were mainly composed of fibrin (55.9  18%) with platelets (16.8  18%), erythrocytes (11.5  9%),
cholesterol crystals (5.2  8.4%), and leukocytes (1.3  2.0%). The median ischemic time was 175 min (inter-
quartile range: 140 to 297). Ischemic time impacted thrombi composition, resulting in a positive correlation with
intracoronary thrombus fibrin content, r  0.38, p  0.01, and a negative correlation with platelet content,
r  0.34, p  0.02. Thus, fibrin content increased with ischemic time, ranging from 48.4  21% (3 h) up to
66.9  9% (6 h) (p  0.02), whereas platelet content decreased from 24.9  23% (3 h) to 9.1  6% (6 h)
(p  0.07). Soluble CD40 ligand was positively correlated to platelet content in the thrombus (r  0.40, p 
0.02) and negatively correlated with fibrin content (r  0.36; p  0.04). Multivariate analysis indicated that
ischemic time was the only predictor of thrombus composition, with a 2-fold increase of fibrin content per isch-
emic hour (adjusted odds ratio: 2.00 [95% confidence interval: 1.03 to 3.7]; p  0.01).
Conclusions In acute STEMI, platelet and fibrin contents of the occlusive thrombus are highly dependent on ischemia time,
which may have a direct impact on the efficacy of drugs or devices used for coronary reperfusion. (J Am Coll
Cardiol 2011;57:1359–67) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.077Acute coronary thrombosis resulting in total occlusion of a
coronary artery leads to ST-segment elevation myocardial
infarction (STEMI) (1). Exposition of the lipid-rich core
after atherosclerosis plaque rupture/erosion into the arterial
lumen triggers the formation of unstable platelet aggregates,
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sulting red thrombus is com-
prised of erythrocytes and in-
flammatory cells entrapped by
the fibrin network. The layered
aspect highlights the repeated
episodes of thrombus growth
(3,4).
It remains unclear how time
affects the dynamic process of
thrombus formation in the coro-
nary arteries of STEMI patients
(5). Data are also scarce on how
thrombus architecture correlates
with coronary reperfusion after
primary percutaneous coronary in-
tervention (PCI) or with periph-
eral blood biomarkers. The in-
creased use of thromboaspiration
in primary PCI for STEMI offers
unique opportunity to study thrombus composition, dynamic
ormation, and architecture in vivo (6–9).
Ischemic time was hypothesized to be among the stron-
est independent correlates of thrombus architecture. We
herefore evaluated the effect of the following plausible
eterminants of thrombus architecture (e.g., coronary anat-
my and reperfusion, patient clinical presentation, periph-
ral blood biomarkers, fibrin clot viscoelastic properties, and
esponse to fibrinolysis). Our aim was to characterize the
ndependent correlates of thrombus architecture and to
ssess whether thrombus architecture per se could affect
yocardial reperfusion.
ethods
tudy design and thrombus collection. Between January
007 and April 2008, we prospectively screened all the
TEMI patients referred to the catheterization laboratory
or primary PCI associated with thromboaspiration per-
ormed by a low-profile catheter (Export 6F, Medtronic,
anta Rosa, California). Thromboaspiration was performed
henever possible (when the anatomy of the coronary
rtery—curve and size—allowed it) in all patients with a
hrombolysis In Myocardial Infarction (TIMI) flow grade
and in all patients with a visible thrombus if TIMI flow
rade was 1 or more.
Collected thrombi were immediately washed with saline
nd fixed with 2% glutaraldehyde in 50 mmol/l Na-
acodylate buffer (pH 7.3).
canning electron microscope analysis. Sample fixation,
ehydration, and preparation were performed according to a
reviously published method (10). High-definition photo-
raphs (3,000 magnification) were obtained using a
hilips/FEI XL20 scanning electron microscope 4-nm res-
lution (FEI, Hillsboro, Oregon) (11). To control for
Abbreviations
and Acronyms
adjOR  adjusted odds
ratio
IQR  interquartile range
MBG  myocardial blush
grade
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SEM  scanning electron
microscopy
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparinomposition heterogeneity in the analysis of the surface of mhrombus, we covered several areas (at least 12 according to
grid and the size of the thrombus) for each thrombus (Fig. 1). A
emiquantitative analysis and a visual approach were used
or the first 10 thrombi. For the semiquantitative analysis,
ach picture was divided into 400 squares (Image J software,
ational Institutes of Health, Bethesda, Maryland), and the
redominant composition (platelet, fibrin, erythrocytes, leu-
ocytes, cholesterol crystal) of each square was noted
Fig. 1) (12). All the structures visualized were easy to
dentify, and crystal-like structures were characterized as
holesterol crystals (asterisks in Fig. 2B) on the basis of
revious SEM images described in vitro (13,14) and the
robability of their presence in the setting of a ruptured
laque exposing a lipid-rich core. The visual approach
onsisted of a careful observation of each pictures with a
ubjective evaluation of the percentage of each component.
ery low interindividual variability was found in the throm-
us composition analysis (6%) between the 2 approaches;
herefore. the time-consuming semiquantitative analysis
as not performed for the remaining 35 thrombi (Figs. 2A
nd 2B). The 2 scientists performing scanning electron
icroscopy (SEM) and analysis were blinded to the clinical
ata.
lood samples and measurement. Blood samples were
rawn from the arterial sheath just after insertion and were
ollected in Vacutainer tubes (Becton Dickinson, Franklin
akes, New Jersey) containing trisodium citrate 0.129 mol/l
3.2% sodium citrate) for routine blood work and for
iomarkers measurements.
Soluble CD40L levels were measured using a human
CD40L ELISA bioassay (Arcus Biological, Modena, It-
ly). TNF- and IL-6 levels were measured by Quantikine
andwich enzyme immunoassays (R&D Systems, Abing-
on, United Kingdom) according to the manufacturer’s
nstructions. CRP levels were quantified by commercially
vailable ELISA kits (Zymutest, Hypen BioMed, Neuville
ur Oise, France). The PAI-1 concentration was measured
sing an Asserachrom PAI-1 kit (Diagnostica Stago, As-
ieres, France). All measures were assessed in duplicate.
hole blood clot viscoelastic properties and lysis rates.
lots were formed in a thermostable 37°C plastic plate by
ecalcifying 700 l of PPP with CaCl2 (10 mmol/l final
oncentration) and 5 l of purified recombinant human
issue factor (Innovin, Dade Behring, Deerfield, Illinois).
o facilitate lysis, 10 l of tissue plasminogen activator
(rt-PA) (0.5 nmol/l final concentration) (Boehringer Ingel-
heim, Ingelheim am Rhein, Germany) was also added.
Plasma clot viscoelastic properties were measured with a
Hemodyne RM-2 Analyser (Hemodyne, Richmond, Vir-
ginia). Fibrinolysis was assessed by continuous monitoring
of the elastic modulus and was expressed as the lysis rate
(s1). The assay accuracy is reportedly similar to that of
etermination of the lysis front velocity (or fiber lysis rate).
lot lysis time was defined as the time needed for the
aximum elastic modulus to decrease by 50%. The intra-
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ously (15).
Data collection. All patients entered the e-PARIS regis-
try, a prospective web-based registry regrouping clinical and
biological data on STEMI patients treated by primary PCI.
Our angiographic core laboratory reviewed all angiographic
films and noted the size of the infarct-related artery,
corrected TIMI frame count, and myocardial blush grade
(MBG), as previously described (16). Clinical and biological
data were analyzed to identify predictors of thrombus
composition. This study was approved by the Institutional
Review Board of the Pitié-Salpêtrière Hospital in Paris
(CPP), France.
Clinical follow-up. Patients were followed-up for 30 days
through out-patient consultation. Physicians noted the occur-
rence of major cardiovascular and cerebrovascular events, in-
cluding death, stroke, recurrent myocardial infarction (MI),
urgent revascularization, and definite and probable stent
thrombosis (Academic Research Consortium definition), as
well as major and minor bleeding events. ST-segment resolu-
Figure 1 Analysis of Clot Surface With 10 Areas
These areas (indicated by the blue circles) were used to average the thrombus hetion data were collected from the patient file.Statistical analysis. Categorical variables were expressed as
percentages, and continuous variables as mean  SD or
medians with the interquartile range (IQR) (25th to 75th
percentiles) for time delay. Association between continuous
variables was assessed by Pearson’s correlation test. The
variable ischemic time had an almost normal distribution.
Because complementary analyses using Pearson’s correlation
test after log-transformation and nonparametric Spearman’s
test found similar results, the variable was considered
normally distributed for all other analyses. Potential associ-
ations between clinical and biological parameters were
tested by Student t test and ANOVA test with Dunnett’s
correction for multiple comparisons. Multivariable logistic
and mixed models were used to assess the relationship
between ischemic time and both qualitative and quantitative
thrombus composition. Covariables (age, diabetes, renal
insufficiency, admission troponin fibrinogen and platelet
levels, pre-hospital abciximab use, clopidogrel pre-treatment,
unfractionated heparin [UFH] versus enoxaparin use, and
coronary artery reference diameter) were introduced into the
eity (A) and perform semiquantitative analysis (B).terogenmodels in addition to ischemic time in a stepwise fashion.
0
A
g
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mixed models to assess the normal distribution of residuals.
Analyses were performed with SAS version 9.2 (SAS Institute,
Cary, North Carolina).
Results
We prospectively screened 349 patients referred for primary
PCI. Sixty-one late presenters were excluded because there
was a time delay of 12 h from symptom onset to PCI or
because symptom onset could not be characterized. Throm-
boaspiration was used in one-third of the early STEMI
presenters (38%), and significant coronary thrombi1 mm3
were successfully retrieved in one-third of them (Fig. 3).
The baseline characteristics of the patients are shown in
Table 1. Patients were treated aggressively, with a high
Figure 2 Scanning Electron Micrograph at 3,000Magnification
(A) This portion is mainly composed of erythrocytes (b) trapped in a fibrin
mesh (c) with few platelet aggregates (d) and rare white cells (a). (B) This
portion is mainly composed of platelet aggregates with a few cholesterol crys-
tals (yellow asterisks).proportion receiving high loading doses of clopidogrel (atleast 600 mg) and abciximab in addition to aspirin and low
molecular weight or UFH. Median ischemic time (from
symptom onset to PCI) was 175 min (IQR: 140 to 297
min). Details of procedures, angiographic findings, bio-
marker distributions, viscoelastic measurements, and fibri-
nolysis results are reported in Table 2.
Thrombus composition. Analyses were performed on 44
of the 45 thrombi collected. One thrombus was not ana-
lyzed because the SEM preparation had failed. Fibrin fibers
were the major thrombus component, representing more
than 60% of their composition. Platelets, erythrocytes,
cholesterol crystals, and leukocytes together comprised the
remaining 40% (Fig. 4). Thrombus components were easily
identified in our high-definition SEM images. The 2
examples shown here are good representatives of the broad
scope of thrombi components. These include a fibrin-and-
erythrocyte composition typical of “old” fibrin-rich thrombi,
usually found in patients with an ischemic time of 3 h
(Fig. 2A) and a “fresh” platelet-rich thrombus of a patient
presenting early, within the first hour following symptom
onset (Fig. 2B). Remarkably, we could identify in these
high-definition images an unexpected percentage (5%) of
cholesterol crystals that were only described previously ex
vivo (13).
Effect of time on thrombus composition. Ischemic time
was found to have a high impact on thrombus composition,
resulting in a positive correlation with intracoronary throm-
bus fibrin content, r  0.38, p  0.01, and a negative
correlation with platelet content r  0.34, p  0.02.
Pearson’s correlation test after log-transformation and
Spearman’s nonparametric correlation test showed similar
results (r  0.39, p  0.01; r  0.34, p  0.025; and r 
.36, p  0.017; r  0.30, p  0.05, respectively).
dditionally, when ischemic time was divided into 3 cate-
ories (3 h, 3 to 6 h, and 6 h), we observed a stepwise
ncrease in fibrin content with respect to prolonged ischemicFigure 3 Flow Chart of the Study
0

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(p  0.02). Platelet content decreased from 24.9  23%
(3 h) to 9.1  6% (6 h) (p  0.07) (Fig. 5). The
evolution of each thrombus component relative to ischemic
time is represented in Figure 6.
Effect of antithrombotic treatment on thrombus composition.
Aspirin was administrated before thromboaspiration in
100% of patients, and abciximab was used either in a
pre-hospital setting or in the catheterization laboratory in
91% of patients, limiting the analysis of their impact on
thrombus composition. Clopidogrel pre-treatment was ad-
Baseline Characteristics (n  45)Table 1 Baseline Characteristics (n  45)
Demographics and risk factors
Age 57.9 13.2
Male 38 (84.4%)
Active smoker 21 (46.6%)
Diabetes 12(26.6%)
Hypertension 16 (35.5%)
Dyslipidemia 30 (66.6%)
BMI 26.4 4.1
Past medical history of
ACS 7 (15.5%)
Angioplasty 6 (13.3%)
CABG 1 (2.2%)
Clinical presentation
Anterior MI 21 (46.6%)
Cardiac arrest 4 (11.1%)
TIMI risk score 3.0 2.1
Killip class 1.2 0.6
Cardiogenic shock 2 (4.4%)
Time delay in min
Symptom onset to medical contact 80 [55–179]
Medical contact to catheterization laboratory 66 [55–128]
Catheterization laboratory to sheath insertion 20 [10–33]
Symptom onset to PCI 175 [140–297]
Biomarkers on admission
Troponin I, g/ml 5.1 13.8
Negative troponin 17 (37.7%)
CK, IU/ml 447 828
CRP, mg/l 13.7 38
Fibrinogen, g/l 3.7 1.3
Platelet, mm3 242 93
Creatinine clearance, ml/min 98 33
Antithrombotic treatment
ASA 45 (100%)
Clopidogrel 37 (83.5%)
Unfractionated heparin 17 (37.7%)
Enoxaparin 26 (62.3%)
GP IIb/IIIa inhibitor 41 (91.1%)
Pre-hospital 8 (17.7%)
Catheterization laboratory 33 (73.3%)
Thrombolysis 1 (2.2%)
Values are mean  SD, n (%), or median [interquartile range].
ACS acute coronary syndrome(s); ASA acetylsalicylic acid; BMI body mass index; CABG
oronary artery bypass grafting; CK creatine kinase; CRP C-reactive protein; GP glycoprotein;
MI  myocardial infarction; PCI  percutaneous intervention; TIMI  Thrombolysis In Myocardial
Infarction.ministered in 29 patients (66%) and did not induce any nsignificant changes on platelet composition (24.1  6% vs.
15.5 3%; p 0.17) when compared with patients without
pre-hospital inhibition of the P2Y12 receptor.
Biomarker distribution, viscoelastic properties, and
fibrinolysis. The peripheral measure of the platelet acti-
vation marker sCD40 ligand was positively correlated
with platelet content in the thrombus (r  0.40, p 
.02) and negatively correlated with fibrin content (r 
0.36; p  0.04). The simultaneous measure of the more
classic biomarker of myocardial infarction, namely tro-
ponin I, was a strong biomarker of ischemic time (r 
0.56, p  0.01), but was not correlated with thrombus
composition. No correlation was seen between ischemic
time and inflammation biomarkers (IL-6, TNF-,
CRPus) or PAI-1, and neither platelet count nor fibrin-
ogen level was correlated with thrombus composition
(data not shown). Patients presenting after 6 h had a
nonsignificant trend towards faster clotting time, stiffer
Angiographic Results, Revascularization Procedure,a d Biological Data (n  45)Table 2 Angiographic Res ts, Revascularization Procedure,and Biological Data (n  45)
Radial approach 42 (93.3%)
Diameter of the infarct-related artery 3.15 0.5
Acute stent thrombosis 5 (11.1%)
Patients with more than 1 significant lesion 13 (28.8%)
Infarct-related artery
LAD 21 (46.6%)
RCA 17 (37.7%)
Cx 6 (13.3%)
CABG 1 (2.2%)
Successful PCI 41 (91.1%)
Ejection fraction post-MI (%) 48.9 12
Markers of reperfusion
TIMI flow grade 3 before PCI 3 (6.6%)
TIMI flow grade 3 after PCI 40 (88.8%)
cTFC before PCI 133 45
cTFC after PCI 25 22
TIMI MBG3 before PCI 4 (8.8%)
TIMI MBG3 after PCI 18 (40%)
ST-segment resolution 70% 25 (55.3)
Biomarkers
CRPus, g/ml 8.5 3.9
IL-6, pg/ml 14.2 34.8
PAI-1, ng/ml 70.2 51.2
sCD40-ligand, ng/ml 1.2 0.6
TNF-alpha, pg/ml 8.6 1.1
Viscoelastic properties and response to fibrinolysis
PCF, kdynes/s 1.4 1.4
Elastic modulus max, kdynes/s 8.7 8.8
Clotting time, s 691 651
Clot lysis time, s 347 204
Lysis rate  104, s1 2.9 4.1
Values are n (%) or mean  SD.
cTFC  corrected Thrombolysis In Myocardial Infarction frame count; CRPus  ultra-sensitive
C-reactive protein; Cx circumflex coronary artery; IL interleukin; LAD left anterior descending
coronary artery; MBG  myocardial blush grade; PAI  plasminogen activator inhibitor; PCF 
platelet contractile force; RCA  right coronary artery; sCD40  soluble CD40; TNF  tumor
ecrosis factor; other abbreviations as in Table 1.
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clot lysis time (Fig. 7).
Independent correlates of thrombus composition and of
reperfusion. Ischemic time was the only correlate of
thrombus composition in the multivariable stepwise logistic
analysis. None of the other covariables met the 0.05 signif-
icance level for entering the model. Every additional isch-
emic hour led to a 2-fold increase in the rates of fibrin-rich
thrombus—30% platelet and 70% fibrin—(adjusted
odds ratio [adjOR]: 2 [95% confidence interval (CI): 1.03 to
3.7]) and a 50% reduction in platelet content (adjOR: 0.5
[95% CI: 0.27 to 0.94]) (p 0.001 for both). Similar results
were obtained when the fibrin content (%) was analyzed
quantitatively in a multivariable mixed model with the same
covariables introduced in the model in addition to ischemic
time. “Fresh” platelet-rich thrombus was defined as 30%
platelet and 70% fibrin, and “old” fibrin-rich thrombi as
30% platelet and 70% fibrin. No differences in reperfu-
ion were seen between “fresh” platelet-rich thrombi and
old” fibrin-rich thrombi assessed by ST-segment resolution
nd TIMI MBG. Independent correlates of successful
eperfusion (ST-segment resolution of 70%) included a
low plasma fibrinogen level (adjOR: 0.33 [95% CI: 0.12 to
0.91] [per g/l], p  0.003) and the use of enoxaparin versus
UFH (adjOR: 10.3 [95% CI: 1.7 to 62], p  0.02). High
nd low counts for plasma fibrinogen level were 8 and
.8 g/l, respectively.
iscussion
hrombus aspiration is a newly recommended technique that
acilitates thrombus removal from the culprit coronary artery in
yocardial infarction. The method reportedly improves mor-
Figure 4 Thrombi Composition in 44 STEMI Patients
(Early Presenters)
Red lines indicate median and interquartile range (25% to 75%). PCI  percu-
taneous intervention; STEMI  ST-segment elevation myocardial infarction.ality in STEMI patients presenting within 12 h of symptomsonset when used in conjunction with primary PCI (7,8). This
life-saving technique allowed us to study prospectively the
composition of occlusive thrombi in STEMI patients admitted
for mechanical coronary reperfusion.
We report the results of a new analysis method for
intracoronary thrombi obtained in vivo that allows the
determination of their precise composition using SEM,
associated here with an analysis of cardiac biomarkers, fibrin
clot viscoelastic properties, and fibrinolysis obtained simul-
taneously from patients’ peripheral blood. The analysis of
high-definition SEM images that we produced with respect
to ischemic time (from symptom onset to thrombus re-
trieval) revealed that the dynamic formation of the throm-
bus during an acute coronary occlusion is a fast-evolving
process. The platelet and fibrin fiber components of the
thrombus, which are both therapeutic targets, changed
rapidly with respect to ischemic time. These observations of
thrombus structure and formation in vivo demonstrate the
relationship between thrombus composition and ischemic time,
which was found to be the only major predictors of
thrombus composition. Our results also demonstrate that
thrombus composition is an indicator of coronary occlusion
time and, therefore, of the beginning of myocardial damage.
Our findings add to the body of knowledge on thrombus
formation in acute MI. First, they confirm, at the patho-
physiological level, the generally accepted pathogenesis of
clot formation in vivo in STEMI patients. “Fresh” thrombi
have the highest proportion of platelets, whereas the pro-
portion of fibrin fibers increases over time, as the level of
thrombin increases, leading to “older” fibrin-rich thrombi.
These results confirm previous in vivo animal studies show-
ing the very early stage of thrombus formation, just after
endothelial injury, when the initial thrombus is primarily
composed of activated platelets, rapidly stabilized by fibrin
Figure 5 Impact of Time on Thrombus Composition
The p values are given for comparison with the group 3 h as a reference with
multiple Student t test. *p  0.05. Multiple comparisons were done with the
Dunnett’s test, resulting in a p  0.044 for fibrin and nonsignificant for plate-
let content.
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(17–19). At a clinical level, our results are along the same
lines as those reported by Kramer et al. (20), who showed
that the thrombus composition itself seems to be a prog-
nostic marker and is linked to short- and long-term mor-
tality in a large study in STEMI. In this previous study,
thrombus composition was evaluated by classical light
microscopy showing 2 types of thrombi, “fresh thrombi”
(1 day) composed of layered patterns of fibrin and
intact platelets, erythrocytes, and granulocytes, and “older
thrombi” (1 day) comprised of lytic and/or organized
areas. Our own analysis differs from this previous classi-
fication by the age of clots (earlier period), the method
used (scanning electronic microscope), the structure an-
alyzed (we studied the thrombus surface, which reflects
more the latter layers of thrombus formation), and the
results reported (focused on the proportion of each
component). The high-resolution imaging facilitated the
detailed characterization of all structures present in the
thrombi, despite the difficulties of this task, because of
their remarkable heterogeneity. This allowed us, for
example, to identify cholesterol crystals that were most
likely released by the ruptured plaque. It should also be
noted that fibrin is a major component of the thrombus
even at the relatively early stages studied here. Addition-
ally, simultaneous measurements of biomarkers allow us
to confirm the role of sCD40 ligand on platelet accumu-
lation in the intracoronary thrombus at the early phase of
formation.
Our findings also help interpret results obtained from
previous clinical trials. Indeed, fibrinolysis treatment has
been demonstrated to have a narrow therapeutic time
Figure 6 Evolution of the Percentage Thrombus Composition fo
The components in percentages (y-axis) are shown relative to ischemic times in mwindow and seems to be most efficient during the first 3 h tof STEMI (21,22). According to our study, this represents
a period when the clot has a small and accessible amount of
fibrin fibers and when fibrinolysis has not yet been overcome
by the intense fibrin formation. Furthermore, the fast
accumulation of fibrin fibers in the thrombus followed by its
stabilization by FXIII cross-linking is likely to increase clot
stiffness, resulting in resistance to fibrinolysis as shown in
vitro (15,23). Regarding antiplatelet agents, even though
glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab,
have been shown to reduce mortality in primary PCI (vs.
placebo), the potential benefit is mostly observed with an
early administration (24–29). In contrast, negative studies
with GP IIb/IIa inhibitors seem to relate to late presenta-
tion of patients (30,31). These clinical results suggest a time
limit under which these molecules are efficient, and corre-
spond according to our study to the time when the occlusive
thrombus contains a high proportion of platelets, shortly
before it evolves into a compact, fibrin-rich structure.
In our study, the effect of antithrombotic pretreatment by
aspirin and abciximab was initially included in the analysis,
but due to the fact that almost all patients received these 2
fast-acting agents before thromboaspiration, we could not
demonstrate any potential effect of such drugs on thrombus
composition. We believe that the impact of pre-hospital
P2Y12 inhibition on platelet composition should be studied
n a dedicated study.
tudy limitations. First, although erythrocytes were the
econd most common cell identified in our thrombi, we
ere surprised not to find an increased percentage of
rythrocytes with time. Erythrocytes in clots were the origin
f the word “red” thrombi for old thrombi as opposed to
ecent platelet-rich “white” thrombi. Erythrocytes may con-
h Component
(x-axis). Lines represent linear regression for correlation with ischemic time.r Eac
inutesribute more to thrombus composition at later stages and
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The role of erythrocytes in thrombi remains to be studied
more extensively, since they also appear to mediate the
formation of thicker fibrin fibers and influence clot vis-
coelasticity by increasing the viscous component of the
sample relative to the elastic component (32). Second, due
to the in vivo nature of our study, the analysis was
Figure 7 Results of Fibrin Clot Viscoelastic Properties and
Response to Fibrinolysis According to Ischemic Time
No significant differences were found between groups with the Dunnett’s test.
EM Max  maximum elastic modulus.performed on the main aspirated piece of the thrombusand did not include the total volume of retrieved frag-
ments or the distal embolic debris. Because the retrieval
of the thrombus is done by aspiration through the
catheter lumen, the high-definition analysis, made by
scanning the surface of the piece of thrombus, can
correspond, in fact, to any part of the thrombus (head or
tail, surface or core, luminal or abluminal), turning this
potential limitation into a major strength of this ap-
proach. To our knowledge, there is no known technique
(beside surgical removal or postmortem autopsy) that can
analyze the whole thrombus, including the part of the
thrombus that might have embolized, or allows analyzing
the 3-dimensional structure of a thrombus. Additionally,
the number of thrombi retrieved, and the random local-
ization of the pictures that were analyzed, should guar-
antee an unbiased measurement, and control for compo-
sition heterogeneity in the pieces of thrombi that were
obtained. Third, potential distortion of the samples
might have occurred during thromboaspiration. How-
ever, we believe that damage was limited, knowing that
thrombi are stiffer than in vitro clots and that fibrin fibers
and clots bear outstanding elastic properties (33,34). The
preserved appearance of cells and fibrin fibers in the
microscopy images confirmed that distortion was mini-
mal. Fourth, the choice of SEM can be criticized since
material cannot be stained as in histopathologic analysis,
but was motivated by its ability to provide high-
resolution images of thrombi in humans who had had MI
(5). Fifth, the aspirated thrombus may be older than
expected from the duration of the ischemic time, and
younger thrombus could be superimposed onto an older
thrombus, thereby potentially confusing our observations
(20). Finally, even if thrombi were retrieved randomly in
a subset of patients representative of our STEMI popu-
lation, the absence of successful thromboaspiration in all
STEMI presenters could have biased our results. A
methodological limitation also needs to be underlined, as
the multivariable analysis should be considered as only
exploratory, because the model is not parsimonious.
Our work helps characterize thoroughly the components
of coronary thrombi in STEMI and thereby contributes to
the current understanding of coronary thrombus formation,
which is relevant to the efficacy of various reperfusion
treatments. The composition of the aspirated thrombus
could also be a potential surrogate end point in clinical trials
assessing the benefit of a new antithrombotic regimen (new
drugs or new combination of drugs). Ongoing research
should elucidate the mechanistic relationships between
thrombus composition, myocardial perfusion, and microvas-
cular obstruction.
Conclusions
Thrombus aspiration, an integral component of mechanical
reperfusion of acute MI, allowed us to describe in detail the
composition of the occlusive thrombus and its changes over
1367JACC Vol. 57, No. 12, 2011 Silvain et al.
March 22, 2011:1359–67 Thrombus Composition in Myocardial Infarctiontime. Our study shows that the platelet and fibrin contents
of the occlusive thrombi of acute STEMI evolve rapidly.
Even within a population of patients treated with aggressive
antithrombotic regimens, ischemic time is a key determi-
nant of thrombus composition.
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